1
|
Soria JC, Ho SN, Varella-Garcia M, Iafrate AJ, Solomon BJ, Shaw AT, Blackhall F, Mok TS, Wu YL, Pestova K, Wilner KD, Polli A, Paolini J, Lanzalone S, Green S, Camidge DR. Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer. Ann Oncol 2019; 29:1964-1971. [PMID: 30010763 DOI: 10.1093/annonc/mdy242] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background In clinical trials of patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) treated with crizotinib, evaluation of the relationship between the percentage of ALK-positive cells by fluorescence in situ hybridization (FISH)-particularly near the cut-off defining positive status-and clinical outcomes have been limited by small sample sizes. Patients and methods Data were pooled from three large prospective trials (one single-arm and two randomized versus chemotherapy) of crizotinib in patients with ALK-positive NSCLC determined by Vysis ALK Break Apart FISH using a cut-off of ≥15% ALK-positive cells. Logistic regression and proportional hazards regression analyses were used to explore the association of percent ALK-positive cells with objective response and progression-free survival (PFS), respectively. Results Of 11 081 screened patients, 1958 (18%) were ALK positive, 7512 (68%) were ALK negative, and 1540 (14%) were uninformative. Median percentage of ALK-positive cells was 58% in ALK-positive patients and 2% in ALK-negative patients. Of ALK-positive patients, 5% had 15%-19% ALK-positive cells; of ALK-negative patients, 2% had 10%-14% ALK-positive cells. Objective response rate for ALK-positive, crizotinib-treated patients with ≥20% ALK-positive cells was 56% (n = 700/1246), 55% (n = 725/1312) for those with ≥15% ALK-positive cells, and 38% for those with 15%-19% ALK-positive cells (n = 25/66). As a continuous variable, higher percentages of ALK-positive cells were estimated to be associated with larger differences in objective response and PFS between crizotinib and chemotherapy; however, tests for interaction between treatment and percentage of ALK-positive cells were not significant (objective response, P = 0.054; PFS, P = 0.17). Conclusions Patients with ALK-positive NSCLC benefit from treatment with crizotinib across the full range of percentage of ALK-positive cells, supporting the clinical utility of the 15% cut-off. The small number of patients with scores near the cut-off warrant additional study given the potential for misclassification of ALK status due to technical or biologic reasons.
Collapse
Affiliation(s)
- J-C Soria
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif; Université Paris-Sud, Orsay, France.
| | - S N Ho
- Global Product Development, Pfizer Oncology, La Jolla
| | - M Varella-Garcia
- Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora
| | - A J Iafrate
- Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, USA
| | - B J Solomon
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - A T Shaw
- Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, USA
| | - F Blackhall
- The Christie Hospital and Institute of Cancer Sciences, Manchester University, Manchester, UK
| | - T S Mok
- Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong
| | - Y-L Wu
- Guangdong General Hospital, Guangdong Lung Cancer Institute, Guangzhou, China
| | | | - K D Wilner
- Global Product Development, Pfizer Oncology, La Jolla
| | - A Polli
- Global Clinical Development and Operations, Pfizer Oncology, Milan, Italy
| | - J Paolini
- Global Clinical Development and Operations, Pfizer Oncology, Milan, Italy
| | - S Lanzalone
- Global Clinical Development and Operations, Pfizer Oncology, Milan, Italy
| | - S Green
- Global Product Development, Pfizer Oncology, Groton, USA
| | - D R Camidge
- Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora
| |
Collapse
|
2
|
Smeltzer M, Wynes M, Lantuejoul S, Soo R, Dalurzo L, Felip E, Hollenbeck G, Howell K, Kerr K, Kim E, Mathias C, Postmus P, Powell C, Ramalingam S, Richeimer K, Taylor M, Tsuboi M, Varella-Garcia M, Wistuba I, Wood K, Scagliotti G, Hirsch F. OA01.09 Comparing Regional Results from the IASLC Global Survey on Molecular Testing in Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
3
|
Varella-Garcia M. I.13 Molecular Testing for Lung Cancer Available in Latin America. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SHI. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol 2019; 30:1121-1126. [PMID: 30980071 PMCID: PMC6637370 DOI: 10.1093/annonc/mdz131] [Citation(s) in RCA: 310] [Impact Index Per Article: 62.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND In the ongoing phase I PROFILE 1001 study, crizotinib showed antitumor activity in patients with ROS1-rearranged advanced non-small-cell lung cancer (NSCLC). Here, we present updated antitumor activity, overall survival (OS) and safety data (additional 46.2 months follow-up) for patients with ROS1-rearranged advanced NSCLC from PROFILE 1001. PATIENTS AND METHODS ROS1 status was determined by FISH or reverse transcriptase-polymerase chain reaction. All patients received crizotinib at a starting dose of 250 mg twice daily. RESULTS Fifty-three patients received crizotinib, with a median duration of treatment of 22.4 months. At data cut-off, treatment was ongoing in 12 patients (23%). The objective response rate (ORR) was 72% [95% confidence interval (CI), 58% to 83%], including six confirmed complete responses and 32 confirmed partial responses; 10 patients had stable disease. Responses were durable (median duration of response 24.7 months; 95% CI, 15.2-45.3). ORRs were consistent across different patient subgroups. Median progression-free survival was 19.3 months (95% CI, 15.2-39.1). A total of 26 deaths (49%) occurred (median follow-up period of 62.6 months), and of the remaining 27 patients (51%), 14 (26%) were in follow-up at data cut-off. Median OS was 51.4 months (95% CI, 29.3 to not reached) and survival probabilities at 12, 24, 36, and 48 months were 79%, 67%, 53%, and 51%, respectively. No correlation was observed between OS and specific ROS1 fusion partner. Treatment-related adverse events (TRAEs) were mainly grade 1 or 2, per CTCAE v3.0. There were no grade ≥4 TRAEs and no TRAEs associated with permanent discontinuation. No new safety signals were reported with long-term crizotinib treatment. CONCLUSIONS These findings serve as a new benchmark for OS in ROS1-rearranged advanced NSCLC, and continue to show the clinically meaningful benefit and safety of crizotinib in this molecular subgroup. TRIAL REGISTRATION NUMBER ClinicalTrials.gov identifier NCT00585195.
Collapse
Affiliation(s)
- A T Shaw
- Department of Medicine, Massachusetts General Hospital Cancer Center, Boston.
| | - G J Riely
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - Y-J Bang
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
| | - D-W Kim
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
| | - D R Camidge
- Division of Medical Oncology, University of Colorado Cancer Center, Aurora, USA
| | - B J Solomon
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - M Varella-Garcia
- Division of Medical Oncology, University of Colorado Cancer Center, Aurora, USA
| | - A J Iafrate
- Department of Medicine, Massachusetts General Hospital Cancer Center, Boston
| | - G I Shapiro
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | - T Usari
- Pfizer Oncology, Milan, Italy
| | | | | | - J W Clark
- Department of Medicine, Massachusetts General Hospital Cancer Center, Boston
| | - S-H I Ou
- Chao Family Comprehensive Cancer Center, University of California, Irvine, USA
| |
Collapse
|
5
|
Shaw A, Riley G, Bang YJ, Kim DW, Camidge D, Varella-Garcia M, Lafrate A, Shapiro G, Winter M, Usari T, Wang S, Wilner K, Clark J, Ou SH. Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.07] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Wright RM, Weigel LK, Varella-Garcia M, Vaitaitis G, Repine JE. Molecular cloning, refined chromosomal mapping and structural analysis of the human gene encoding aldehyde oxidase (AOX1), a candidate for the ALS2 gene. Redox Rep 2016; 3:135-44. [DOI: 10.1080/13510002.1997.11747101] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
7
|
Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R, Varella-Garcia M, Thatcher N, Hirsch FR. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Ann Oncol 2016; 27:1573-9. [PMID: 27207107 PMCID: PMC4959928 DOI: 10.1093/annonc/mdw214] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2016] [Accepted: 05/13/2016] [Indexed: 01/04/2023] Open
Abstract
SQUIRE was a phase III study of gemcitabine and cisplatin with or without necitumumab in patients with metastatic squamous NSCLC. The majority of SQUIRE patients had EGFR protein expressing tumors. Similar to SQUIRE ITT, patients with EGFR protein expressing tumors benefitted from addition of necitumumab to chemotherapy with a safety profile consistent with that of the overall SQUIRE population. Background SQUIRE demonstrated addition of necitumumab to gemcitabine and cisplatin significantly improved survival in patients with stage IV sq-NSCLC. Here, we report additional outcomes for the subpopulation of patients with tumor epidermal growth factor receptor (EGFR) protein expression. Patients and methods Patients with pathologically confirmed stage IV sq-NSCLC were randomized 1:1 to receive a maximum of six 3-week cycles of gemcitabine (1250 mg/m2 i.v., days 1 and 8) and cisplatin (75 mg/m2 i.v., day 1) chemotherapy with or without necitumumab (800 mg i.v., days 1 and 8). Patients in the chemotherapy plus necitumumab group with no progression continued on necitumumab alone until disease progression or intolerable toxicity. SQUIRE included mandatory tissue collection. EGFR protein expression was detected by immunohistochemistry (IHC) in a central laboratory. Exploratory analyses were pre-specified for patients with EGFR protein expressing (EGFR > 0) and non-expressing (EGFR = 0) tumors. Results A total of 982 patients [90% of intention-to-treat (ITT)] had evaluable IHC results. The large majority of these patients (95%) had tumor samples expressing EGFR protein; only 5% had tumors without detectable EGFR protein. Overall survival (OS) for EGFR > 0 patients was significantly longer in the necitumumab plus gemcitabine–cisplatin group than in the gemcitabine–cisplatin group {stratified hazard ratio (HR) 0.79 [95% confidence interval (CI) 0.69, 0.92; P = 0.002]; median 11.7 months (95% CI 10.7, 12.9) versus 10.0 months (8.9, 11.4)}. Additionally, an OS benefit was seen in all pre-specified subgroups in EGFR > 0 patients. However, OS HR for EGFR = 0 was 1.52. Adverse events of interest with the largest difference between treatment groups in EGFR > 0 patients (Grade ≥3) were hypomagnesemia (10% versus <1%) and skin rash (6% versus <1%). Conclusions In line with SQUIRE ITT, addition of necitumumab to gemcitabine–cisplatin significantly prolonged OS and was generally well tolerated in the subpopulation of patients with EGFR-expressing advanced sq-NSCLC. The benefit from addition of necitumumab to chemotherapy was not apparent in this analysis for the small subgroup of patients with non-EGFR-expressing tumors. Clinical Trial NCT00981058.
Collapse
Affiliation(s)
- L Paz-Ares
- Department of Medical Oncology, Hospital Universitario Doce de Octubre & CNIO, Madrid, Spain
| | - M A Socinski
- Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, USA
| | - J Shahidi
- Oncology Clinical Development, Eli Lilly and Company, Bridgewater, USA
| | - R R Hozak
- Oncology Patient Tailoring, Eli Lilly and Company, Indianapolis, USA
| | - V Soldatenkova
- Global Statistical Science, Oncology, Eli Lilly and Company, Bad Homburg, Germany
| | - R Kurek
- Oncology Clinical Development, Eli Lilly and Company, Bad Homburg, Germany
| | - M Varella-Garcia
- Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
| | - N Thatcher
- Department of Medical Oncology, The Christie Hospital, Manchester, UK
| | - F R Hirsch
- Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
| |
Collapse
|
8
|
Saichaemchan S, Ariyawutyakorn W, Varella-Garcia M. Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy. Curr Mol Med 2016; 16:40-62. [DOI: 10.2174/1566524016666151222144231] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2015] [Revised: 11/18/2015] [Accepted: 12/15/2015] [Indexed: 11/22/2022]
|
9
|
Trabelsi S, Mama N, Ladib M, Popov S, Burford A, Mokni M, Tlili K, Krifa H, Varella-Garcia M, Jones C, Tahar Yacoubi M, Saad A, H’mida Ben Brahim D. Adult recurrent pilocytic astrocytoma: Clinical, histopathological and molecular study. Neurochirurgie 2015; 61:392-7. [DOI: 10.1016/j.neuchi.2015.07.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2015] [Revised: 06/09/2015] [Accepted: 07/29/2015] [Indexed: 11/24/2022]
|
10
|
Morton JJ, Bird G, Keysar SB, Astling DP, Lyons TR, Anderson RT, Glogowska MJ, Estes P, Eagles JR, Le PN, Gan G, McGettigan B, Fernandez P, Padilla-Just N, Varella-Garcia M, Song JI, Bowles DW, Schedin P, Tan AC, Roop DR, Wang XJ, Refaeli Y, Jimeno A. XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene 2015; 35:290-300. [PMID: 25893296 PMCID: PMC4613815 DOI: 10.1038/onc.2015.94] [Citation(s) in RCA: 99] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2014] [Revised: 02/20/2015] [Accepted: 03/03/2015] [Indexed: 12/14/2022]
Abstract
The limitations of cancer cell lines have led to the development of direct patient derived xenograft (PDX) models. However, the interplay between the implanted human cancer cells and recruited mouse stromal and immune cells alters the tumor microenvironment and limits the value of these models. To overcome these constraints, we have developed a technique to expand human hematopoietic stem and progenitor cells (HSPCs) and use them to reconstitute the radiation-depleted bone marrow of a NOD/SCID/IL2rg−/− (NSG) mouse on which a patient’s tumor is then transplanted (XactMice). The human HSPCs produce immune cells that home into the tumor and help replicate its natural microenvironment. Despite previous passage on nude mice, the expression of epithelial, stromal, and immune genes in XactMice tumors aligns more closely to that of the patient tumor than to those grown in non-humanized mice – an effect partially facilitated by human cytokines expressed by both the HSPC progeny and the tumor cells. The human immune and stromal cells produced in the XactMice can help recapitulate the microenvironment of an implanted xenograft, reverse the initial genetic drift seen after passage on non-humanized mice, and provide a more accurate tumor model to guide patient treatment.
Collapse
Affiliation(s)
- J J Morton
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine
| | - G Bird
- Department of Dermatology, University of Colorado School of Medicine
| | - S B Keysar
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine
| | - D P Astling
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine.,Department of Biostatistics and Informatics, University of Colorado School of Medicine
| | - T R Lyons
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine
| | - R T Anderson
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine
| | - M J Glogowska
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine
| | - P Estes
- Department of Dermatology, University of Colorado School of Medicine
| | - J R Eagles
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine
| | - P N Le
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine
| | - G Gan
- Department of Radiation Oncology, University of Colorado School of Medicine
| | - B McGettigan
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine
| | - P Fernandez
- Department of Pathology, University of Colorado School of Medicine
| | - N Padilla-Just
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine
| | - M Varella-Garcia
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine
| | - J I Song
- Department of Otolaryngology, University of Colorado School of Medicine
| | - D W Bowles
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine
| | - P Schedin
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine
| | - A-C Tan
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine.,Department of Biostatistics and Informatics, University of Colorado School of Medicine
| | - D R Roop
- Department of Dermatology, University of Colorado School of Medicine.,Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, University of Colorado School of Medicine, Aurora, CO, USA
| | - X-J Wang
- Department of Pathology, University of Colorado School of Medicine.,Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, University of Colorado School of Medicine, Aurora, CO, USA
| | - Y Refaeli
- Department of Dermatology, University of Colorado School of Medicine.,Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, University of Colorado School of Medicine, Aurora, CO, USA
| | - A Jimeno
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine.,Department of Otolaryngology, University of Colorado School of Medicine.,Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, University of Colorado School of Medicine, Aurora, CO, USA
| |
Collapse
|
11
|
Shaw A, Ou S, Bang Y, Camidge R, Solomon B, Salgia R, Riely G, Varella-Garcia M, Shapiro G, Costa D, Doebele R, Le L, Zheng Z, Stephenson P, Shreeve S, Tye L, Christensen J, Wilner K, Clark J, Iafrate A. Clinical Activity of Crizotinib in Ros1-Rearranged Non-Small Cell Lung Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.78] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Bennati C, Chiari R, Metro G, Iacono D, Varella-Garcia M, Aisner D, Minotti V, Meacci M, Paglialunga L, Ludovini V, De Angelis V, Marcomigni L, Tofanetti F, Baglivo S, Bellezza G, Crinò L. Clinical Features and Outcome in Never-Smoker (Ns) Non-Small Cell Lung Cancer (Nsclc) Patients (Pts): a Single-Institution Observational Analysis. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
13
|
Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, Berge EM, Kim J, Sasaki H, Park S, Kryukov G, Garraway LA, Hammerman PS, Haas J, Andrews SW, Lipson D, Stephens PJ, Miller VA, Varella-Garcia M, Jänne PA, Doebele RC. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013; 19:1469-1472. [PMID: 24162815 PMCID: PMC3823836 DOI: 10.1038/nm.3352] [Citation(s) in RCA: 454] [Impact Index Per Article: 41.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2013] [Accepted: 08/15/2013] [Indexed: 12/31/2022]
Abstract
We identified novel gene fusions in patients with lung cancer harboring the kinase domain of the NTRK1 gene that encodes the TRKA receptor. Both the MPRIP-NTRK1 and CD74-NTRK1 fusions lead to constitutive TRKA kinase activity and are oncogenic. Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity inhibited autophosphorylation of TRKA and cell growth. Three of 91 lung cancer patients (3.3%), without known oncogenic alterations, assayed by NGS or FISH demonstrated evidence of NTRK1 gene fusions.
Collapse
Affiliation(s)
- A Vaishnavi
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO
| | - M Capelletti
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA
| | - A T Le
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO
| | - S Kako
- University of Colorado Cancer Center, Aurora, CO
| | - M Butaney
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA
| | - D Ercan
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA
| | - S Mahale
- University of Colorado Cancer Center, Aurora, CO
| | - K D Davies
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO
| | - D L Aisner
- University of Colorado Cancer Center, Aurora, CO.,Department of Pathology, University of Colorado School of Medicine, Aurora, CO
| | - A B Pilling
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO
| | - E M Berge
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO
| | - J Kim
- Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - H Sasaki
- Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - S Park
- Department of Thoracic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | | | - L A Garraway
- Broad Institute, Cambridge, MA.,Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
| | - Peter S Hammerman
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA
| | - J Haas
- Array BioPharma, Boulder, CO
| | | | - D Lipson
- Foundation Medicine, Inc., Boston, MA
| | | | | | - M Varella-Garcia
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.,University of Colorado Cancer Center, Aurora, CO
| | - P A Jänne
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.,Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA
| | - R C Doebele
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.,University of Colorado Cancer Center, Aurora, CO
| |
Collapse
|
14
|
Ragusa M, Flacco A, Ludovini V, Bianconi F, Vannucci J, Bellezza G, Sidoni A, Varella-Garcia M, Crinò L, Puma F. P-126PROGNOSTIC SIGNIFICANCE OF MYC AND HUMAN TELOMERASE GENE AMPLIFICATION IN SURGICALLY TREATED EARLY STAGE NON-SMALL CELL LUNG CANCER. Interact Cardiovasc Thorac Surg 2013. [DOI: 10.1093/icvts/ivt288.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Ludovini V, Flacco A, Bianconi F, Ragusa M, Vannucci J, Bellezza G, Chiari R, Minotti V, Pistola L, Tofanetti FR, Siggillino A, Baldelli E, Sidoni A, Daddi N, Puma F, Varella-Garcia M, Crinò L. Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients. Cancer Chemother Pharmacol 2013; 71:671-80. [PMID: 23314677 PMCID: PMC3963139 DOI: 10.1007/s00280-012-2056-y] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2012] [Accepted: 12/12/2012] [Indexed: 12/15/2022]
Abstract
BACKGROUND Insulin-like growth factor 1 receptor (IGF1R) represents a novel molecular target in non-small-cell-lung cancer (NSCLC). IGF1R and epidermal growth factor receptor (EGFR) activation are essential to mediate tumor cell survival, proliferation, and invasion. This study investigates the prognostic role of IGF1R and EGFR in surgically resected NSCLC. MATERIALS AND METHODS IGF1R and EGFR copy number gain (CNG) were tested by fluorescence in situ hybridization (FISH) and protein expression by immunohistochemistry (IHC) in 125 stage I-II-IIIA NSCLC patients. RESULTS Fourty-six tumors (40.3%) were IGF1R FISH-positive (FISH+), and 76 (67.2%) were EGFR FISH+. Tumors with concomitant IGF1R/EGFR FISH+ were observed in 34 cases (30.1%). IGF1R and EGFR FISH+ were associated with SCC histology (p = 0.01 and p = 0.04, respectively). IGF1R and EGFR protein over-expression (IHC+) were detected in 45 (36.0%) and 69 (55.2%) cases, respectively. Tumors with concomitant IGF1R/EGFR IHC+ were detected in 31 (24.8%) patients. IGF1R/EGFR FISH+ and IGF1R/EGFR IHC+ were significantly associated (χ(2) = 4.02, p = 0.04). Patients with IGF1R/EGFR FISH+ and IGF1R/EGFR IHC+ were associated with shorter disease-free survival (DFS) (p = 0.05 and p = 0.05, respectively). Patients with concomitant IGF1R/EGFR FISH+/IHC+ had a worse DFS and overall survival (p = 0.005 and p = 0.01, respectively). The multivariate model confirmed that IGF1R/EGFR FISH+/IHC+ (hazard ratio (HR), 4.08; p = 0.01) and tumor stage (II-III vs I) (HR, 4.77; p = 0.003) were significantly associated with worse DFS. CONCLUSIONS IGF1R/EGFR FISH+ correlates with IGF1R/EGFR IHC+. IGF1R/EGFR FISH+/IHC+ is an independent negative prognostic factor for DFS in early NSCLC. These features may have important implications for future anti-IGF1R therapeutic approaches.
Collapse
Affiliation(s)
- V Ludovini
- Department of Medical Oncology, S. Maria Della Misericordia Hospital, 1, G. Dottori Street, 06132 Perugia, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Rudin C, Durinck S, Stawiski E, Poirier J, Modrusan Z, Bergbower E, Illei P, Varella-Garcia M, Minna J, Seshagiri S. 552 Comprehensive Genomic Profiling of Small Cell Lung Cancer Reveals SOX2 Amplification and MYCL1 Rearrangements. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72349-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
17
|
Bang YJ, Ou S, Camidge D, Clark J, Wilner K, Tye L, Stephenson P, Varella-Garcia M, Iafrate A, Shaw A. Clinical Activity of Crizotinib in Advanced Non-Small-Cell Lung Cancer (NSCLC) Harboring ROS1 Gene Rearrangement. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32008-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
18
|
Ou S, Camidge D, Engelman J, Clark J, Tye L, Wilner K, Stephenson P, Varella-Garcia M, Iafrate A, Shaw A. Clinical Activity of Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Ros1 Gene Rearrangement. Ann Oncol 2012. [DOI: 10.1093/annonc/mds408] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Minuti G, Cappuzzo F, Duchnowska R, Jassem J, Fabi A, O'Brien T, Mendoza AD, Landi L, Biernat W, Czartoryska-Arłukowicz B, Jankowski T, Zuziak D, Zok J, Szostakiewicz B, Foszczyńska-Kłoda M, Tempińska-Szałach A, Rossi E, Varella-Garcia M. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer 2012; 107:793-9. [PMID: 22850551 PMCID: PMC3425981 DOI: 10.1038/bjc.2012.335] [Citation(s) in RCA: 95] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Background: To investigate whether copy number gain of MET or hepatocyte growth factor (HGF) affect trastuzumab sensitivity in HER2-positive metastatic breast cancer (MBC). Methods: We analysed 130 HER2-positive MBC treated with trastuzumab-based therapy. MET and HGF gene copy numbers (GCN) were assessed by fluorescence in situ hybridisation (FISH) in primary breast cancer samples. Receiver operating characteristic analysis was applied to find the best cutoff point for both MET and HGF GCN. Results: MET FISH-positive cases (N=36, mean ⩾3.72) had a significantly higher trastuzumab failure rate (44.4% vs 16.0% P=0.001) and a significantly shorter time to progression (5.7 vs 9.9 months; HR 1.74; P=0.006) than MET FISH-negative cases (N=94, mean <3.72). Hepatocyte growth factor GCN was evaluated in 84 cases (64.6%). Receiver operating characteristic analysis identified 33 HGF FISH-positive patients (mean HGF GCN ⩾3.01). HGF FISH-positive status was significantly associated with higher risk of failure (30.3% vs 7.8% P=0.007) as compared with HGF FISH-negative cases (N=51, mean <3.01). MET and HGF FISH-positive status was highly correlated (P<0.001) and combination of both biomarkers did not increase predictive value of either considered separately. Conclusion: High GCNs of MET and HGF associate with an increased risk of trastuzumab-based therapy failure in HER2-positive MBC.
Collapse
Affiliation(s)
- G Minuti
- Department of Medical Oncology, Civil Hospital of Livorno, Istituto Toscano Tumori, Viale Alfieri 36, Livorno 57100, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Minuti G, Duchnowska R, Jassem J, Roncalli M, O'Brien T, Fabi A, Landi L, Di Marsico R, Biernat W, Czartoryska-Arlukowicz B, Jankowski T, Zuziak D, Zok J, Szostakiewicz B, Foszczynska-Kloda M, Tempinska-Szalach A, Rossi E, Varella-Garcia M, Cappuzzo F. P5-13-07: MET and Hepatocyte Growth Factor (HGF) Increased Gene Copy Number Is Associated to Trastuzumab Failure in HER2 Positive Metastatic Breast Cancer (MBC). Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-13-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The ErbB2-targeting monoclonal antibody trastuzumab has remarkable efficacy in metastatic breast cancer (MBC) patients (pts) with HER2 overexpression or amplification (HER2+), either alone or in combination with chemotherapy. However, the response rate to trastuzumab is modest and not all pts derive benefit from this treatment. Predictive mechanisms of sensitivity and/or resistance are largely unknown. Recently, preclinical and limited clinical data showed that aberrant MET expression in MBC is a predictor of poor prognosis and is involved in trastuzumab resistance. Aim of the present study was to investigate whether increased gene copy number of MET or its ligand, the hepatocyte growth factor (HGF), affect trastuzumab sensitivity.
Patients and Methods: This retrospective study included 130 HER2+ MBC pts treated with trastuzumab as monotherapy (N=21) or in combination with chemotherapy (N=109). Main inclusion criteria were presence of at least one measurable lesion and availability of paraffin-embedded tumor tissue from primary cancer. MET and HGF gene copy number (GCN) were assessed by fluorescence in situ hybridization (FISH). Receiver operating characteristic (ROC) analysis was used for identifying the best MET and HGF mean GCN cut-off.
Results: In the whole population response rate (RR), including complete (CR) and partial response (PR) was 49.2%, disease control rate, including CR+PR+ stable disease (SD) was 76.2%, median time to progression (TTP) 9.4 months, and median survival (OS) 28.3 months. MET FISH analysis was successfully performed in all 130 cases. Median MET mean GCN was 2.96 (range 1.66−8.40), with no gene amplification. ROC curve identified a mean of 3.72 MET GCN as the optimal cut-off value for discriminating between sensitive (CR+PR+SD) and refractory pts (pts with progressive disease [PD] at the first disease assessment). MET FISH+ (N=36, mean ≥3.72) had a significantly higher PD rate (44.4% versus 16.0%; p=0.001) and a significantly shorter TTP (5.7 versus 9.9 months; HR 1.74 95% C.I. 1.16−2.62; p=0.006) than MET FISH- pts (N=94, mean <3.72). HGF GCN was successfully evaluated in 84 pts (64.6%). Median HGF mean GCN was 2.80 (range 1.14−6.90). ROC analysis identified a cut-off of 3.01 mean HGF GCN as the best discriminating between sensitive (CR+PR+SD) and refractory pts. HGF FISH+ (N=33, mean ≥ 3.01) had a significantly higher PD rate (30.3% versus 7.8%; p=0.007) and a non-significant shorter TTP (9.9 versus 10.5 months, HR 1.10 95% C.I. 0.70−1.74, p=0.66).
Conclusions: High GCNs of MET or HGF associate with an increased risk of trastuzumab failure in HER2+ MBC. These data support a further development of combining anti-HER2 with anti-MET strategies in MBC.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-13-07.
Collapse
Affiliation(s)
- G Minuti
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - R Duchnowska
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - J Jassem
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - M Roncalli
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - T O'Brien
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - A Fabi
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - L Landi
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - R Di Marsico
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - W Biernat
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - B Czartoryska-Arlukowicz
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - T Jankowski
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - D Zuziak
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - J Zok
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - B Szostakiewicz
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - M Foszczynska-Kloda
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - A Tempinska-Szalach
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - E Rossi
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - M Varella-Garcia
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| | - F Cappuzzo
- 1Istituto Toscano Tumori, Civil Hospital of Livorno, Livorno, Italy; Military Institute of Medicine, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Milan University, Istituto Clinico Humanitas, Milan, Italy; Laboratory of Molecular Pathology, University of Colorado Cancer Center, Denver, CO; National Cancer Institute Regina Elena, Rome, Italy; Bialystok Oncology Center, Bialystok, Bialystok, Poland; Lublin Oncology Center, Lublin, Poland; Beskidy Oncology Center, Bielsko-Biala, Poland, Bielsko-Biala, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; West Pomeranian Oncology Center, Szczecin, Poland; District Hospital, Elblag, Poland; CINECA Interuniversity Consortium, Bologna, Italy
| |
Collapse
|
21
|
Toschi L, Colombo P, Soldani C, Giordano L, Finocchiaro G, Siracusano L, Gianoncelli L, Incarbone M, Destro A, Alloisio M, Terracciano L, Varella-Garcia M, Cappuzzo F, Roncalli M, Viola A, Santoro A. Prognostic role of nitrotyrosines in surgically resected non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Hout D, Nickols J, Xue L, Skokan M, Tang X, Morris S, Varella-Garcia M, Wistuba II. Initial validation of a highly sensitive RT-qPCR assay for detecting all fusions and wild-type upregulation of ALK. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Iafrate AJ, Shapiro G, Costa DB, Butaney M, Ou SI, Maki RG, Bang Y, Varella-Garcia M, Salgia R, Wilner KD, Kulig K, Selaru P, Tang Y, Kwak EL, Clark JW, Camidge DR. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7507] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Ludovini V, Flacco A, Bianconi F, Tofanetti FR, Ragusa M, Vannucci J, Bellezza G, Mameli MG, Chiari R, Minotti V, Pistola L, Siggillino A, Baldelli E, Sidoni A, Puma F, Varella-Garcia M, Crinò L. Insulin-like growth factor receptor-1 (IGF1R) and epidermal growth factor receptor (EGFR) amplification and expression in surgically resected NSCLC. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Flacco A, Ludovini V, Tofanetti FR, Bianconi F, Bellezza G, Mameli MG, Metro G, Bennati C, Cagini L, Daddi N, Pistola L, Siggillino A, Baldelli E, Sidoni A, Puma F, Varella-Garcia M, Crinò L. MYC and human telomerase gene (TERC) gene copy number gain in resected in non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10580] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
26
|
Huang W, Skokan M, Chang Y, Wu C, Lee J, Feser W, Barón AE, Bunn PA, Varella-Garcia M. Changes in molecular profile following platinum chemotherapy in NSCLC. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Sartore-Bianchi A, Fieuws S, Veronese S, Moroni M, Personeni N, Frattini M, Torri V, Cappuzzo F, Vander Borght S, Martin V, Skokan M, Santoro A, Gambacorta M, Tejpar S, Varella-Garcia M, Siena S. Standardization of EGFR FISH in colorectal cancer: Results of an international, interlaboratory reproducibility ring study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
|
29
|
Flaig TW, Su L, Thorburn A, Frankel AE, Li Y, Woo JH, Varella-Garcia M, La Rosa FG, Li C, Yang X. DAB 389 EGF for the treatment of superficial urothelial cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
255 Background: Intravesical BCG has remained the standard treatment for superficial bladder cancer for decades, despite frequent recurrences after its use. Toxic fusion proteins are a novel class of agents containing both a targeting and a treatment component; correspondingly, DAB389EGF contains an EGF and a diphtheria element, thereby targeting any cell expressing EGFR. Notably, the normal urothelium has little or no luminal EGFR expression in contrast to urothelial cancers, which frequently overexpress EGFR. Methods: DAB389EGF was tested in vitro to determine the effect of DAB389EGF on cell viability in culture. Tests of clonogenicity were performed by treating plated cells for 2 hours and following colony counts over 14 days. DAB389EGF was tested in an orthotopic murine model of bladder cancer with implanted HTB9 cells modified to express luciferase. DAB389EGF was administered intravesically via catheterization of the murine bladder and held in place for 2 hours with a temporary suture to close the urethra. Treatments were continued twice weekly for 2 weeks, with DT-GMCSF used as a control. Results: Treatment with DAB389EGF yielded IC50's ranging from 0.5 to 15.7 ng/ml in 8 tested bladder cancer cell lines, but the IC50 was > 500ng/ml in the EGFR- negative H520 control cell line. A single 2-hour exposure to DAB389EGF (50ng/ml) decreased colony formation in all of the bladder cancer cell lines, with complete suppression in HT1376 and T24 cells. In the animal model, luciferase activity was lost in 5 of 6 mice treated with DAB389EGF, versus 1 of 6 mice treated with control. After the 2 week treatment period, histological assessment of the treated mice was undertaken and was consistent with the luciferase findings. FISH was used to detect human or murine-originated cells in order to confirm the presence or absence of xenograft tissue histologically. Conclusions: Targeted-toxin fusion proteins represent a novel treatment approach for superficial bladder cancer. By capitalizing on the differential expression of EGFR between cancerous and normal urothelium, DAB389EGF selectively targets bladder cancer cells. Preliminary animal studies support the efficacy and tolerability of this approach with additionally animal work currently underway. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. W. Flaig
- University of Colorado Denver, Aurora, CO; Scott and White Hospital, Temple, TX
| | - L. Su
- University of Colorado Denver, Aurora, CO; Scott and White Hospital, Temple, TX
| | - A. Thorburn
- University of Colorado Denver, Aurora, CO; Scott and White Hospital, Temple, TX
| | - A. E. Frankel
- University of Colorado Denver, Aurora, CO; Scott and White Hospital, Temple, TX
| | - Y. Li
- University of Colorado Denver, Aurora, CO; Scott and White Hospital, Temple, TX
| | - J. H. Woo
- University of Colorado Denver, Aurora, CO; Scott and White Hospital, Temple, TX
| | - M. Varella-Garcia
- University of Colorado Denver, Aurora, CO; Scott and White Hospital, Temple, TX
| | - F. G. La Rosa
- University of Colorado Denver, Aurora, CO; Scott and White Hospital, Temple, TX
| | - C. Li
- University of Colorado Denver, Aurora, CO; Scott and White Hospital, Temple, TX
| | - X. Yang
- University of Colorado Denver, Aurora, CO; Scott and White Hospital, Temple, TX
| |
Collapse
|
30
|
Varella-Garcia M, Cho Y, Lu X, Barón AE, Terracciano L, Camidge DR, Bunn PA, Franklin WA, Cappuzzo F, Doebele RC. ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10533] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, Nagelmeier I, Rüschoff J, Schmitt M, Arbogast S, Cappuzzo F. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol 2010; 62:970-7. [PMID: 19861557 PMCID: PMC2771853 DOI: 10.1136/jcp.2009.066548] [Citation(s) in RCA: 97] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
There is a need for predictive biomarkers that identify non-small-cell lung cancer (NSCLC) patients most likely to respond to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. There are numerous potential candidates, although none has been proven in prospective clinical trials. The EGFR gene copy number evaluated by fluorescence in situ hybridisation (FISH) has been highlighted as one of the most effective markers for sensitivity to EGFR TKIs in large phase III, randomised placebo-controlled trials and has been used in clinical settings to assist physicians in defining the therapeutic regimen. The EGFR FISH assay has technical challenges and it is critical that detailed guidelines are provided to help clinical laboratories in performing and interpreting the test. Excellent assay reproducibility and portability rates among laboratories are crucial to guarantee that accurate clinical decisions can be made for patients with NSCLC. This article discusses the consensus outcomes of a global workshop convened to discuss key technical issues and standardise reading strategies for the EGFR FISH assay of NSCLC tumour tissue.
Collapse
Affiliation(s)
- M Varella-Garcia
- University of Colorado Cancer Center, Aurora, Colorado 80045, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Sastre J, Aranda E, Grávalos C, Massutí B, Varella-Garcia M, Rivera F, Soler G, Carrato A, Manzano JL, Díaz-Rubio E, Hidalgo M. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol 2009; 77:78-84. [PMID: 20042346 DOI: 10.1016/j.critrevonc.2009.11.005] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2009] [Revised: 11/10/2009] [Accepted: 11/26/2009] [Indexed: 12/11/2022] Open
Abstract
PURPOSE to evaluate the efficacy and safety of first-line single-agent cetuximab in fit elderly patients with metastatic colorectal cancer, as well as potential molecular predictive factors for efficacy. PATIENTS AND METHODS patients aged 70 or older with metastatic CRC without criteria for frailty and no prior treatment for advanced disease were treated with single-agent cetuximab 400mg/m(2) followed by weekly 250mg/m(2) until disease progression or unacceptable toxicity. RESULTS forty-one patients were included. Two patients achieved a complete response and 4 patients had a partial response for an overall response rate of 14.6%. Fifteen patients (36.6%) remained stable. Median time to progression was 2.9 months and median overall survival 11.1 months despite two-third of patients received chemotherapy at progression. Forty-five percent of EGFR gene copy number positive patients by FISH were progression-free at 12 weeks, in contrast with 12% of FISH negative patients (p=0.04). Grade 3 skin toxicity was reported in 5 patients (12.2%). Hypersensitivity infusion reactions were not reported and there were no toxic deaths. CONCLUSION cetuximab is a safe monoclonal antibody with moderate activity in first-line metastatic colorectal cancer, but the present study does not support the use of cetuximab as single-agent in first-line fit elderly patients with metastatic CRC.
Collapse
Affiliation(s)
- J Sastre
- HC San Carlos, Madrid, Center affíliated to the Red Temática de Investigación Cooperativa (RD06/0020/0021), Instituto Carlos III, Spanish Ministry of Science and Innovation, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Kono S, Tan A, Bunn P, Davies A, Doebele R, Oton A, Hirsch F, Varella-Garcia M, Franklin W, Camidge D. PP117 Increased EGFR gene copy number is variably associated with both EGFR and KRAS Mutation (Mt) status and influences Progression Free Survival (PFS) to first-line chemotherapy in EGFR/KRAS wildtype (WT) patients. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)72177-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
34
|
Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, Toschi L, Incarbone M, Cavina R, Terracciano L, Roncalli M, Alloisio M, Varella-Garcia M, Franklin WA, Santoro A. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol 2009; 21:562-567. [PMID: 19767315 DOI: 10.1093/annonc/mdp357] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND The purpose of this study is to investigate the prognostic role of insulin-like growth factor receptor 1 (IGF1R) expression in surgically resected non-small-cell lung cancer (NSCLC). Patient characteristics and methods: This retrospective study was conducted in 369 stage I-II-IIIA, surgically resected, NSCLC patients. Patients exposed to anti-epidermal growth factor receptor (EGFR) agents were excluded. IGF1R expression was evaluated by immunohistochemistry in tissue microarray sections. RESULTS A positive IGF1R expression (score > or = 100) was observed in 282 cases (76.4%) and was significantly associated with squamous cell histology (P = 0.04) and with grade III differentiation (P = 0.02). No difference in survival was observed between the positive and negative group when score 100 was used as cut-off for discriminating a positive versus a negative IGF1R result (52 versus 48 months, P = 0.99) or when median value of IGF1R expression was used (45 versus 55 months, P = 0.36). No difference in survival was observed between IGF1R-positive and -negative patients in a subgroup of stage I-II adenocarcinoma (n = 137) with known EGFR mutation and copy number status. CONCLUSIONS IGF1R expression does not represent a prognostic factor in resected NSCLC patients. Patients with squamous cell carcinoma overexpress IGF1R more frequently than patients with nonsquamous histology, justifying the different sensitivity to anti-IGF1R agents observed in clinical trials.
Collapse
Affiliation(s)
- F Cappuzzo
- Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano.
| | - G Tallini
- Department of Pathology, Ospedale Bellaria, Bologna, Italy
| | - G Finocchiaro
- Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano
| | - R S Wilson
- University of Colorado Cancer Center, Aurora, CO, USA
| | - C Ligorio
- Department of Pathology, Ospedale Bellaria, Bologna, Italy
| | - L Giordano
- Statitistic Unit, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
| | - L Toschi
- Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano
| | - M Incarbone
- Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano
| | - R Cavina
- Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano
| | - L Terracciano
- Division of Molecular Pathology, University Hospital, Basel, Switzerland
| | - M Roncalli
- Department of Pathology, University of Milan School of Medicine, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
| | - M Alloisio
- Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano
| | | | - W A Franklin
- University of Colorado Cancer Center, Aurora, CO, USA
| | - A Santoro
- Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano
| |
Collapse
|
35
|
Abstract
Epidermal growth factor receptor (EGFR) and HER2 are cell surface receptor tyrosine kinases (TKs) that transduce growth signals through dimerization with HER family receptors. The heterodimerization of EGFR with HER2 induces a more potent activation of EGFR TK than does EGFR homodimerization. When tumor cells overexpress both EGFR and HER2, they exhibit aggressive tumor cell growth, owing to the increased potential for EGFR/HER2 heterodimerization and signaling. Gefitinib and erlotinib are EGFR TK inhibitors (EGFR TKIs) and have antitumor activity in 8-18% of patients with advanced non-small-cell lung cancer (NSCLC). Certain patient subsets are particularly responsive to EGFR TKIs. Analyses of biomarkers from patients in clinical studies of EGFR TKIs show correlations between objective tumor response and EGFR overexpression, as detected by immunohistochemistry and increased gene copy number measured by fluorescence in situ hybridization analysis. Furthermore, NSCLC tumors that overexpress both EGFR and HER2 are more sensitive to EGFR TKIs than are tumors that overexpress EGFR but are HER2 negative. Therefore, the measurement of EGFR and HER2 protein expression and the gene copy number in NSCLC tumors may have a prognostic value in NSCLC and a predictive value for identifying patients likely to benefit from an EGFR TKI. These considerations suggest that the simultaneous inhibition of EGFR and HER2 may warrant further study in patients with NSCLC.
Collapse
Affiliation(s)
- F R Hirsch
- Department of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA.
| | | | | |
Collapse
|
36
|
Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Rzyman W, Jassem J, Bunn PA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGF1R) protein expression, mRNA expression and gene copy number in operable non-small cell lung cancer (NSCLC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7524] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7524 Background: IGF1R is a promising target for NSCLC therapy. We have evaluated IGF1R protein expression, mRNA expression and gene copy number in primary tumors from surgically treated NSCLC patients (pts) as a reference for correlative biomarker studies in trials using IGF1R inhibitors. Methods: The study included 189 consecutive NSCLC pts who underwent curative pulmonary resection. There were 24% females, 54% squamous cell carcinomas (SCC), 29% adenocarcinomas (AC), 3% large cell carcinomas, 14% other histologies; p stage I: 41%, pII: 22%, pIII: 32% and pIV: 4%. IGF1R expression was evaluated in tissue microarrays by immunohistochemistry (IHC) with Ventana CONFIRM (N=179) and Novus (#NB600–559) anti-IGF1R Ab scored by two observers (H score 0–400). IGF1R gene copy number was assessed by FISH using customized probes (N=181). IGF1R gene expression was evaluated using qRT-PCR from 114 corresponding fresh-frozen samples. Results: Patterns of IHC staining were different for the Ventana and the Novus Ab (inverse correlation, r=-0.16, p=0.04, N=177). IGF1R protein expression detected by Ventana Ab (> median score) was more frequent in SCC (76%) than AC and other histologies (14%, p<0.001) and in pts with higher stage (p=0.03) but was not associated with survival (p=0.46). IGF1R H score by Ventana Ab, but not by Novus Ab, correlated with mRNA expression (r=0.37, p<0.001). IGF1R mRNA expression tended to be higher in SCC than in other histologies (p=0.089), but did not associate with other clinical features or survival (p=0.73). According to criteria previously established for EGFR, IGF1R gene copy number by FISH showed 5 tumors with gene amplification (2.8%), 43 tumors - high polysomy (23.8%), 87 tumors - low polysomy (48.1%), and 46 tumors - trisomy/disomy (25.4%). Pts with gene amplification/high polysomy had 3-yr survival of 60% (95% CI 47% - 74%) vs. 48% (38% - 59%) for low polysomy and 35% (21% - 49%) for trisomy/disomy pts (p=0.016). Prognostic value of IGF1R gene copy number was confirmed in the multivariate analysis. Conclusions: IGF1R protein expression is higher in SCC. IGF1R protein and gene expression does not associate with survival, whereas high IGF1R gene copy number associates with better prognosis in operable NSCLC. [Table: see text]
Collapse
Affiliation(s)
- R. Dziadziuszko
- Medical University of Gdansk, Gdansk, Poland; University of Colorado Health Sciences Center, Aurora, CO
| | - D. T. Merrick
- Medical University of Gdansk, Gdansk, Poland; University of Colorado Health Sciences Center, Aurora, CO
| | - S. E. Witta
- Medical University of Gdansk, Gdansk, Poland; University of Colorado Health Sciences Center, Aurora, CO
| | - A. D. Mendoza
- Medical University of Gdansk, Gdansk, Poland; University of Colorado Health Sciences Center, Aurora, CO
| | - B. Szostakiewicz
- Medical University of Gdansk, Gdansk, Poland; University of Colorado Health Sciences Center, Aurora, CO
| | - W. Rzyman
- Medical University of Gdansk, Gdansk, Poland; University of Colorado Health Sciences Center, Aurora, CO
| | - J. Jassem
- Medical University of Gdansk, Gdansk, Poland; University of Colorado Health Sciences Center, Aurora, CO
| | - P. A. Bunn
- Medical University of Gdansk, Gdansk, Poland; University of Colorado Health Sciences Center, Aurora, CO
| | - M. Varella-Garcia
- Medical University of Gdansk, Gdansk, Poland; University of Colorado Health Sciences Center, Aurora, CO
| | - F. R. Hirsch
- Medical University of Gdansk, Gdansk, Poland; University of Colorado Health Sciences Center, Aurora, CO
| |
Collapse
|
37
|
Witta SE, Franekova V, Yoshida K, Igolnikov I, Frederick B, Varella-Garcia M, Bunn PA, Hirsch FR. Synergistic effect of SNDX-275 with lapatinib or erlotinib in breast, lung, or head and neck cancer cell lines expressing HER- 2. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e14566] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14566 Background: We previously demonstrated the synergistic effect of the histone deacetylase inhibitor SNDX-275 and gefitinib in non-small cell lung cancer (NSCLC) cell lines lacking E-cadherin expression. We evaluated the combination effect of SNDX- 275 with erlotinib or lapatinib in lung, head and neck (H&N) and breast cancer cell lines resistant to erlotinib or lapatinib(IC50> 1uM) and expressing Her2. Methods: This study included 10 H&N and 17 NSCLC cell lines, 2 breast cancer cell lines with expressing Her2 (SK BR3, MCF7) and one lacking Her2 expression, MDA-MB231. Cell lines were incubated for 5 days with increasing concentrations (0.16, 1 and 6μM) of SNDX-275, lapatinib and erlotinib alone or in combination. The growth inhibitory effect was analyzed with MTT assay. The combination drug effect was evaluated using CalcuSyn (Cambridge, UK). E-cadherin and Her2 expression was evaluated using microarray analysis and RT-PCR. Her2 was considered positive if the relative expression was >300 by RT-PCR. Protein expression was analyzed with western blots. Results: Among the 17 NSCLC and 10 H&N cell lines 16 (12 NSCLC and 4 H&N) had positive Her2 RNA expression. 2 NSCLC (A549, H1703) and 2 H&N (UMSCC10, UMSCC19) were resistant to erlotinib or lapatinib (IC50>1μM). The 2 breast cancer cell lines 2, MCF7 and MDA-MB-321, were resistant to erlotinib and lapatinib. SNDX-275 increased the expression of E-cadherin in 5 of the 6 cell lines selected (A549, H1703, UMSCC19, MCF7 and MDA- MB-321). Synergistic effect of SNDX-275 1μM and lapatinib 1μM was detected in the MCF7, UMSCC10, UMSCC19 cell lines (Combination Index, CI: 0.09, 0.9, 0.67; respectively), while SNDX-275 1μM and erlotinib 1μM were synergistic in MCF7, MDA-MB-321, H1703 and A549 (CI: 0.2, 0.95, 0.58, 0.32; respectively). Conclusions: The combination of SNDX-275 and erlotinib or lapatinib is active in breast, NSCLC, H&N cell lines resistant to either drug alone. [Table: see text]
Collapse
Affiliation(s)
- S. E. Witta
- University of Colorado Health Sciences Center, Aurora, CO
| | - V. Franekova
- University of Colorado Health Sciences Center, Aurora, CO
| | - K. Yoshida
- University of Colorado Health Sciences Center, Aurora, CO
| | - I. Igolnikov
- University of Colorado Health Sciences Center, Aurora, CO
| | - B. Frederick
- University of Colorado Health Sciences Center, Aurora, CO
| | | | - P. A. Bunn
- University of Colorado Health Sciences Center, Aurora, CO
| | - F. R. Hirsch
- University of Colorado Health Sciences Center, Aurora, CO
| |
Collapse
|
38
|
Witta SE, Dziadziuszko R, Yoshida K, Hedman K, Varella-Garcia M, Bunn PA, Hirsch FR. ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). Ann Oncol 2009; 20:689-95. [PMID: 19150934 DOI: 10.1093/annonc/mdn703] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Epidermal growth factor receptor (EGFR) inhibitors are effective in a subset of patients with non-small-cell lung cancer (NSCLC). We previously showed that E-cadherin expression associates with gefitinib activity. Here, we correlated the expressions of ErbB-3 and E-cadherin in NSCLC tumors and cell lines, their effect on response to gefitinib, and induction of both by the histone deacetylase (HDAC) inhibitors vorinostat and SNDX-275. METHODS Real-time RT-PCR was carried out on RNA isolated from 91 fresh-frozen NSCLC samples and from 21 NSCLC lines. Protein expression was evaluated with western blot and flow cytometry. Apoptosis was assessed using vibrant apoptosis assay. RESULTS Expressions of E-cadherin and ErbB-3 correlated significantly in primary tumors (r = 0.38, P < 0.001) and in cell lines (r = 0.88, P < 0.001). Cotransfection of ErbB-3 and E-cadherin in a gefitinib-resistant cell line showed enhanced apoptotic response to gefitinib. vorinostat and SNDX-275 induced ErbB-3 and E-cadherin in gefitinib-resistant cell lines. When gefitinib-resistant lines were treated with vorinostat and gefitinib, synergistic effects were detected in four of the five lines tested. CONCLUSION ErbB-3 and E-cadherin are coexpressed and induced by HDAC inhibitors. For tumors with low ErbB-3 and E-cadherin expressions, the combination of HDAC and EGFR-tyrosine kinase inhibitors increased expression of both genes and produced more than additive apoptotic effect.
Collapse
Affiliation(s)
- S E Witta
- Department of Medicine-Division of Medical Oncology, University of Colorado Health Sciences Center and University of Colorado Cancer Center, Aurora, CO 80010, USA.
| | | | | | | | | | | | | |
Collapse
|
39
|
Majka SM, Skokan M, Wheeler L, Harral J, Gladson S, Burnham E, Loyd JE, Stenmark KR, Varella-Garcia M, West J. Evidence for cell fusion is absent in vascular lesions associated with pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2008; 295:L1028-39. [PMID: 18931051 DOI: 10.1152/ajplung.90449.2008] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Pulmonary arterial hypertension (PAH) is a fatal disease associated with severe remodeling of the large and small pulmonary arteries. Increased accumulation of inflammatory cells and apoptosis-resistant cells are contributing factors. Proliferative apoptosis-resistant cells expressing CD133 are increased in the circulation of PAH patients. Circulating cells can contribute to tissue repair via cell fusion and heterokaryon formation. We therefore hypothesized that in the presence of increased leukocytes and CD133-positive (CD133(pos)) cells in PAH lung tissue, cell fusion and resulting genomic instability could account for abnormal cell proliferation and the genesis of vascular lesions. We performed analyses of CD45/CD133 localization, cell fusion, and proliferation during late-stage PAH in human lung tissue from control subjects and subjects with idiopathic (IPAH) and familial (FPAH) PAH. Localization, proliferation, and quantitation of cell populations in individual patients were performed by immunolocalization. The occurrence of cellular fusion in vascular lesions was analyzed in lung tissue by fluorescence in situ hybridization. We found the accumulation of CD45(pos) leukocytic cells in the tissue parenchyma and perivascular regions in PAH patients and less frequently observed myeloid cells (CD45/CD11b). CD133(pos) cells were detected in occlusive lesions and perivascular areas in those with PAH and were more numerous in those with IPAH lesions than in FPAH lesions. Cells coexpressing CD133 and smooth muscle alpha-actin were occasionally observed in occlusive lesions and perivascular areas. Proliferating cells were more prominent in IPAH lesions and colocalized with CD45 or CD133. We found no evidence of increased ploidy to suggest cell fusion. Taken together, these data suggest that abnormal lesion formation in PAH occurs in the absence of cell fusion.
Collapse
Affiliation(s)
- S M Majka
- Cardiovascular Pulmonary Research, University of Colorado Denver, Aurora, Colorado 80045, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Cappuzzo F, Jänne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, Zucali PA, Terracciano L, Toschi L, Roncalli M, Destro A, Incarbone M, Alloisio M, Santoro A, Varella-Garcia M. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2008; 20:298-304. [PMID: 18836087 DOI: 10.1093/annonc/mdn635] [Citation(s) in RCA: 246] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND MET amplification has been detected in approximately 20% of non-small-cell lung cancer patients (NSCLC) with epidermal growth factor receptor (EGFR) mutations progressing after an initial response to tyrosine kinase inhibitor (TKI) therapy. PATIENTS AND METHODS We analyzed MET gene copy number using FISH in two related NSCLC cell lines, one sensitive (HCC827) and one resistant (HCC827 GR6) to gefitinib therapy and in two different NSCLC patient populations: 24 never smokers or EGFR FISH-positive patients treated with gefitinib (ONCOBELL cohort) and 182 surgically resected NSCLC not exposed to anti-EGFR agents. RESULTS HCC827 GR6-resistant cell line displayed MET amplification, with a mean MET copy number >12, while sensitive HCC827 cell line had a mean MET copy number of 4. In the ONCOBELL cohort, no patient had gene amplification and MET gene copy number was not associated with outcome to gefitinib therapy. Among the surgically resected patients, MET was amplified in 12 cases (7.3%) and only four (2.4%) had a higher MET copy number than the resistant HCC827 GR6 cell line. CONCLUSIONS MET gene amplification is a rare event in patients with advanced NSCLC. The development of anti-MET therapeutic strategies should be focused on patients with acquired EGFR-TKI resistance.
Collapse
Affiliation(s)
- F Cappuzzo
- Department of Oncology-Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Pitts T, Kaufman S, Tentler J, Leong S, Coldren C, Hirsch F, Varella-Garcia M, Eckhardt S. 91 POSTER Development and characterization of predictive markers to the IGF-1R inhibitor, PQIP, in colorectal cancer (CRC). EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72023-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
42
|
Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L, Holmes AJ, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A, Jänne PA. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 2008; 99:83-9. [PMID: 18577988 PMCID: PMC2453041 DOI: 10.1038/sj.bjc.6604439] [Citation(s) in RCA: 144] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
The impact of KRAS mutations on cetuximab sensitivity in epidermal growth factor receptor fluorescence in situ hybridisation-positive (EGFR FISH+) metastatic colorectal cancer patients (mCRC) has not been previously investigated. In the present study, we analysed KRAS, BRAF, PI3KCA, MET, and IGF1R in 85 mCRC treated with cetuximab-based therapy in whom EGFR status was known. KRAS mutations (52.5%) negatively affected response only in EGFR FISH+ patients. EGFR FISH+/KRAS mutated had a significantly lower response rate (P=0.04) than EGFR FISH+/KRAS wild type patients. Four EGFR FISH+ patients with KRAS mutations responded to cetuximab therapy. BRAF was mutated in 5.0% of patients and none responded to the therapy. PI3KCA mutations (17.7%) were not associated to cetuximab sensitivity. Patients overexpressing IGF1R (74.3%) had significantly longer survival than patients with low IGF1R expression (P=0.006), with no difference in response rate. IGF1R gene amplification was not detected, and only two (2.6%) patients, both responders, had MET gene amplification. In conclusion, KRAS mutations are associated with cetuximab failure in EGFR FISH+ mCRC, even if it does not preclude response. The rarity of MET and IGF1R gene amplification suggests a marginal role in primary resistance. The potential prognostic implication of IGF1R expression merits further evaluation.
Collapse
Affiliation(s)
- F Cappuzzo
- Department of Medical Oncology, Istituto Clinico Humanitas IRCCS, Milan University, Rozzano, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Olsen CC, Paulus R, Komaki R, Varella-Garcia M, Dziadziuszko R, Curran WJ, Robert F, Choy H, Blumenschein GR, Hirsch FR. RTOG 0324: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients with stage IIIA/B non-small cell lung cancer (NSCLC)—Association between EGFR gene copy number and patients’ outcome. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.7607] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Finocchiaro G, Cappuzzo F, Rossi E, Toschi L, Janne PA, Roncalli M, Ligorio C, Rimassa L, Santoro A, Varella-Garcia M. Insuline like growth factor receptor-1 (IGFR-1), MET, and BRAF and primary resistance to cetuximab therapy in colorectal cancer patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4135] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Cappuzzo F, Skokan M, Gajapathy S, Giordano L, Incarbone M, Roncalli M, Terracciano L, Alloisio M, Santoro A, Varella-Garcia M. Effect of increased MET gene copy number on survival of surgically resected non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.11047] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Varella-Garcia M, Ladanyi M, Kris MG, Li A, Chitale DA, Rekhtman N, Riely GJ, Miller VA, Hirsch FR, Zakowski MF. Comparison of CISH and FISH for detection of EGFR copy number in lung adenocarcinoma and correlation with EGFR and KRAS mutation status and EGFR immunoreactivity. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.22105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Zucali PA, Ruiz MG, Giovannetti E, Destro A, Varella-Garcia M, Floor K, Ceresoli GL, Rodriguez JA, Garassino I, Comoglio P, Roncalli M, Santoro A, Giaccone G. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008; 19:1605-12. [PMID: 18467317 DOI: 10.1093/annonc/mdn240] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Approximately 10% of unselected non-small-cell lung cancer (NSCLC) patients responded to the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, resistance mechanisms are not well understood. We evaluated several potential biological markers of intrinsic EGFR-TKIs-resistance in NSCLC. MATERIALS AND METHODS pAKT, pERK, cSRC, E-cadherin, cMET[pY1003], cMET[pY1230/1234/1235], and cMET[pY1349] immunohistochemistry, cMET FISH analysis, and EGFR-, KRAS-, and cMET mutation analysis were carried out on tumor samples from 51 gefitinib-treated NSCLC patients. Biological parameters and survival end points were compared by univariate and multivariate analyses. cMET expression was also investigated in two additional series of patients. The in vitro antiproliferative activity of gefitinib alone or in combination with hepatocyte growth factor and the cMET antibody DN-30 was assessed in NSCLC cells. RESULTS EGFR19 deletion and pAKT expression were significantly associated with response (P < 0.0001) and longer time to progression (TTP) (P = 0.007), respectively. Strong cMET[pY1003] membrane immunoreactivity was expressed in 6% of 149 tumors analyzed and was significantly associated with progressive disease (P = 0.019) and shorter TTP (P = 0.041). In vitro, the DN-30 combination synergistically (CI < 1) enhanced gefitinib-induced growth inhibition in all cMET[pY1003]-expressing cell lines studied. CONCLUSIONS Activated cMET[pY1003] appears to be a marker of primary gefitinib resistance in NSCLC patients. cMET may be a target in treatment of NSCLC.
Collapse
Affiliation(s)
- P A Zucali
- Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Vendrame-Goloni CB, Carvalho-Salles AB, Ruiz MA, Ricci Júnior O, Varella-Garcia M, Fett-Conte AC. Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH. Genet Mol Res 2008; 7:417-23. [PMID: 18551408 DOI: 10.4238/vol7-2gmr396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Investigation of the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in chronic myeloid leukemia patients is essential to predict prognosis and survival. In 20 patients treated at the Bone Marrow Transplantation Unit of São José do Rio Preto (São Paulo, Brazil), we used fluorescence in situ hybridization (FISH) to investigate the frequency of cells with BCR/ABL rearrangement at diagnosis and at distinct intervals after allo-HSCT until complete cytogenetic remission (CCR). We investigated the disease-free survival, overall survival in 3 years and transplant-related mortality rates, too. Bone marrow samples were collected at 1, 2, 3, 4, 6, 12, and 24 months after transplantation and additional intervals as necessary. Success rate of the FISH analyses was 100%. CCR was achieved in 75% of the patients, within on average of 3.9 months; 45% patients showed CCR within 60 days after HSCT. After 3 years of the allo-HSCT, overall survival rate was 60%, disease-free survival was 50% and the transplant-related mortality rate was 40%. The study demonstrated that the BCR-ABL FISH assay is useful for follow-up of chronic myeloid leukemia patients after HSCT and that the clinical outcome parameters in our patient cohort were similar to those described for other bone marrow transplantation units.
Collapse
Affiliation(s)
- C B Vendrame-Goloni
- Departamento de Biologia, Instituto de Biociências Letras e Ciências Exatas, Universidade Estadual Paulista, São José do Rio Preto, SP, Brasil.
| | | | | | | | | | | |
Collapse
|
49
|
Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA, Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 2008; 19:1053-9. [PMID: 18304967 DOI: 10.1093/annonc/mdn006] [Citation(s) in RCA: 185] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND Allelic loss in chromosome 3p is one of the most frequent and earliest genetic events in lung carcinogenesis. We investigated if the loss of microRNA-128b, a microRNA located on chromosome 3p and a putative regulator of epidermal growth factor receptor (EGFR), correlated with response to targeted EGFR inhibition. Loss of microRNA-128b would be equivalent to losing a tumor suppressor gene because it would allow increased expression of EGFR. PATIENTS AND METHODS We initially showed that microRNA-128b is a regulator of EGFR in non-small-cell lung cancer (NSCLC) cell lines. We tested microRNA-128b expression levels by quantitative RT-PCR, genomic copy number by quantitative PCR, and mutations in the mature microRNA-128b by sequencing. We determined whether microRNA-128b loss of heterozygosity (LOH) in 58 NSCLC patient samples correlated with response to gefitinib and evaluated EGFR expression and mutation status. RESULTS We determined that microRNA-128b directly regulates EGFR. MicroRNA-128b LOH was frequent in tumor samples and correlated significantly with clinical response and survival following gefitinib. EGFR expression and mutation status did not correlate with survival outcome. CONCLUSION Identifying microRNA regulators of oncogenes could have far-reaching implications for lung cancer patients including improving patient selection for targeted agents, development of novel therapeutics, or development as early biomarkers of disease.
Collapse
Affiliation(s)
- G J Weiss
- TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, AZ, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Zhong CH, Prima V, Liang X, Frye C, McGavran L, Meltesen L, Wei Q, Boomer T, Varella-Garcia M, Gump J, Hunger SP. E2A-ZNF384 and NOL1-E2A fusion created by a cryptic t(12;19)(p13.3; p13.3) in acute leukemia. Leukemia 2008; 22:723-9. [PMID: 18185522 DOI: 10.1038/sj.leu.2405084] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
A 5-year-old boy who initially presented with ALL and relapsed 4 months later with AML was found to have an add(19) in the leukemia cells. FISH revealed that the add(19) was really a cryptic t(l2;l9)(p13.3;p13.3) interrupting E2A (TCF3). Nucleotide sequences of cloned genomic fragments with the E2A rearrangements revealed that the der(12) contained E2A joined to an intron of the NOLI (p120) gene. Reverse transcriptase (RT)-PCR of patient lymphoblast RNA showed expression of in-frame fusion cDNAs consisting of most of NOL1 fused to the 3' portion of E2A that encoded part of the second transcriptional activation domain and the DNA binding and protein dimerization motifs. The reciprocal der(19) E2A genomic rearrangements included 5' regions of E2A joined to an intron of the ZNF384 (NMP4, CIZ) gene, located approximately 450 kb centromeric to NOL1 on chromosome 12. RT-PCR showed expression of in-frame E2A-ZNF384 fusion cDNAs. To our knowledge, this is the second report of a chromosome translocation in leukemia resulting in two different gene fusions. This is the first report of expression of E2A fusion protein that includes the DNA binding and protein dimerization domains due to a more proximal break in E2A compared to those described previously.
Collapse
Affiliation(s)
- C-h Zhong
- Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|